Immune Thrombocytopenia News and Research

RSS
ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions enters into definitive agreement to acquire Cangene

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

One-quarter of ITP patients achieve 5-year treatment-free response

One-quarter of ITP patients achieve 5-year treatment-free response

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

FDA approves changes to REMS for Nplate and Promacta

FDA approves changes to REMS for Nplate and Promacta

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Massive clotting can destroy placenta and cause miscarriages

Massive clotting can destroy placenta and cause miscarriages

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

SuppreMol completes successful pre-IND meeting with U.S. FDA

SuppreMol completes successful pre-IND meeting with U.S. FDA

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

WinRho SDF for ITP: Cangene announces new safety information

WinRho SDF for ITP: Cangene announces new safety information

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen to present updated data on Nplate at the 2009 ASH meeting